Prescription drug · ANDA
cephalexin NDC 71205-553
Cephalexin 250 mg/5mL · For suspension · Oral · Proficient Rx LP
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71205-553-00 | 71205055300 | 100 mL in 1 BOTTLE (71205-553-00)Marketed from Apr 7, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- cephalexin
- Generic name (nonproprietary)
- cephalexin
- Active ingredients
- Cephalexin — 250 mg/5mL
- Dosage form
- For suspension
- Route
- Oral
- Labeler
- Proficient Rx LP
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 065234
- Marketing start
- Listing expires
- Other FDA classes
- Cephalosporins (Chemical structure)
- Identifiers
- Product ID 71205-553_ff4b7d77-f5bf-4286-a4a3-9bb13949ad35SPL ID ff4b7d77-f5bf-4286-a4a3-9bb13949ad35SPL set ID 829244bd-93da-4a5a-a257-890cfec4c06dRxCUI 309113UNII OBN7UDS42YUPC 0371205553005
- Pharmacologic class
- Cephalosporin Antibacterial
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471205055300followed by a unit qualifier and the quantityPackage 71205-0553-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Cephalexin USP is a cephalosporin antibacterial drug indicated for the treatment of the following infections caused by susceptible isolates of designated bacteria: • Respiratory tract infection ( 1.1 ) • Otitis media ( 1.2 ) • Skin and skin structure infections ( 1.3 ) • Bone infections ( 1.4 ) • Genitourinary tract infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, cephalexin for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Respiratory Tract Infections Cephalexin for oral suspension is indicated for the treatm…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 065234
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| cephalexin | Cephalexin 250 mg/5mL | For suspensionOral | A-S Medication Solutions | 50090-7091 |
| cephalexin | Cephalexin 250 mg/5mL | For suspensionOral | A-S Medication Solutions | 50090-6445 |
| cephalexin | Cephalexin 250 mg/5mL | For suspensionOral | Preferred Pharmaceuticals Inc. | 68788-8686 |
| cephalexin | Cephalexin 125 mg/5mL | For suspensionOral | Lupin Pharmaceuticals, Inc. | 68180-440 |
| cephalexin | Cephalexin 250 mg/5mL | For suspensionOral | Lupin Pharmaceuticals, Inc. | 68180-441 |
| cephalexin | Cephalexin 250 mg/5mL | For suspensionOral | NuCare Pharmaceuticals,Inc. | 68071-3587 |